AUTX-703

A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
69 patients (estimated)
Sponsors
Auron Therapeutics, Inc.
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
2088
NCT Identifier
NCT06846606

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.